Please select the option that best describes you:
What are your top takeaways from SGO 2024?
SGO 2024 was a great meeting with many excellent presentations. We are truly “moving the needle together”. The following presentations are each practice changing.
Duska et al., PMID 38521086: Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer...
Sign In or Register to read more
Answer from: Radiation Oncologist at Community Practice
SGO 2024 had a lot of updates of previously presented clinical trials - many of them from the ESMO conference from last year. So there were not many earth-shattering findings there.A) A few important updates of previous studies:RUBY study - looking at the addition of dostarlimab IO to chemo for adva...